RxDoctor Payments Data

Mary Ann McHenry

Family · Statesville, NCNPI 1437512217

Payments from drug & device makers

$6,409in general payments, 2019–2025

Across 145 payments — averaging $44.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Medtronic$1K
  • Boston Scientific$559
  • Astellas Pharma US Inc$404
  • Pfizer$282
  • Endo Pharmaceuticals Inc.$223
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,47823%
  • Food & beverage$4,85276%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,409 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,323
Medicare patients
245
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron69$79,012
MyrbetriqMirabegron75$64,797
Estradiol72$4,647
Potassium Citrate ErPotassium Citrate43$3,987
Tamsulosin Hcl295$3,601
Cephalexin75$1,245
Solifenacin Succinate35$1,224
Finasteride94$1,194
Alfuzosin Hcl ErAlfuzosin Hcl30$801
Methenamine Hippurate13$797
Testosterone Cypionate18$747
Oxybutynin Chloride ErOxybutynin Chloride70$706
NitrofurantoinNitrofurantoin Macrocrystal21$658
Ciprofloxacin Hcl78$617
Doxycycline Monohydrate15$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$198$79,01269 claims
Astellas Pharma US IncMyrbetriq$404$64,79775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →